Skip to main content
S&P 5007,670.84-0.17%DOW51,349.92-0.26%NASDAQ26,797.54-0.09%GOLD$4,210.50+0.74%OIL$89.25-0.15%
Delayed
Smart Investors Daily
SE

NASDAQ · SEER

Seer, Inc.

Healthcare · Biotechnology

$2.15

Up+$0.12 (+5.91%)

Updated Sep 30, 2026, 6:42 AM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
101.26M
P/E ratio
-1.29
Dividend yield
0.00%
52-week range
$1.55 – $2.41
Volume
583.35K
Avg. volume
127.71K

Price performance · SEER

SEER price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 29, 2026

SEER closed at $2.15 after 20 trading sessions, up 10.82% for the selected period.

Last close
$2.15
Period change
+10.82%
Period low
$1.80
Period high
$2.15
Daily close
View OHLC price history
SEER OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 29, 2026$2.03$2.16$2.0005$2.15583.35K
Sep 28, 2026$1.90$2.06$1.90$2.03699.07K
Sep 25, 2026$1.88$1.955$1.865$1.91244.11K
Sep 24, 2026$1.80$1.90$1.78$1.87767.63K
Sep 23, 2026$1.86$1.87$1.80$1.80157.13K
Sep 22, 2026$1.89$1.895$1.85$1.8669.21K
Sep 21, 2026$1.90$1.915$1.85$1.8686.6K
Sep 18, 2026$1.91$1.91$1.84$1.86563.37K
Sep 17, 2026$1.91$1.94$1.89$1.92212.27K
Sep 16, 2026$1.90$1.94$1.8936$1.90147.25K
Sep 15, 2026$1.90$1.92$1.89$1.90181.45K
Sep 14, 2026$1.94$1.945$1.90$1.91161.27K
Sep 11, 2026$1.94$1.955$1.94$1.9584.22K
Sep 10, 2026$1.94$1.97$1.93$1.93152.53K
Sep 9, 2026$1.94$1.96$1.93$1.94147.7K
Sep 8, 2026$1.94$1.98$1.932$1.95193.74K
Sep 4, 2026$1.93$1.96$1.93$1.9568.81K
Sep 3, 2026$1.96$1.97$1.93$1.9467.75K
Sep 2, 2026$1.94$2.005$1.94$1.98121.19K
Sep 1, 2026$1.96$1.98$1.93$1.94411.46K

Latest SEER news

The latest Smart Investors Daily articles mentioning SEER.

Stock researchCompany · Overview

Company

OverviewForecastEarnings — requires Earnings Calls and Results accessDividend — requires Dividend Research accessFinancials

Market Activity

OptionsInsider Trades — requires Insider Buying and Selling accessShort InterestInstitutional Ownership — requires Institutional Ownership accessSentiment

SEER research

Overview

Company profile and research snapshot.

Company profile

Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.06
Implied upside
—
Analysts
7
SEER recent ratings
DateFirmRatingTarget
May 4, 2026Canaccord GenuityBuy—
Aug 13, 2024Morgan StanleyEqual-Weight—
Mar 5, 2024Morgan StanleyEqual-Weight—
Feb 21, 2023Morgan StanleyEqual-Weight—
Jan 4, 2023B of A SecuritiesUnderperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026

John Chambers, PhD, and Nilanjana Sadhu, PhD, to share early insights from pioneering population-scale proteomic study of 10,000 participants in SingaporeREDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the 2026 Human Proteome Organization (HUPO) World Congress, taking place September 27 to October 1 at the Suntec Singapore Conventi

Yahoo · Sep 21, 2026

Seer Announces CFO Transition

REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the Company’s President, Chief Financial Officer and Treasurer, will depart Seer effective October 1, 2026, to pursue a new opportunity at a private company. Charles Endweiss, who has been Seer’s Vice President, Financial Planning & Analysis, will serve as Treasurer, principal financia

Yahoo · Sep 16, 2026

Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale

Six years after Seer’s foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, disease biology and population healthREDWOOD CITY, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer in deep, unbiased proteomics, today announced that its Proteograph® Product Suite has been used by researchers in more than 100 peer-reviewed scientific

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By